^
Association details:
Biomarker:RAS wild-type
Cancer:Colorectal Cancer
Drug:Bavencio (avelumab) (PD-L1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer

Published date:
11/23/2017
Excerpt:
CAVE mCRC, a single arm multi-centre phase II study, aims to evaluate the efficacy of avelumab and cetuximab in RAS WT mCRC pts treated in first line with chemotherapy (CT) in combination with anti-EGFR drugs…At this preliminary analysis, avelumab plus cetuximab as a rechallenge strategy is effective and well tolerated in chemorefractory RAS/BRAF WT mCRC pts.